α-Tocopheryl Succinate Inhibits Osteoclast Formation by Suppressing Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) Expression and Bone Resorption
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: Osteoclasts are bone-resorbing multinucleated cells derived from the monocyte/macrophage lineage during normal and pathological bone turnover. Recently, several studies revealed that alpha-tocopheryl succinate (αTP-suc)have demonstrated potent anti-cancer activities in vitro and in vivo. However, the effects of αTP-suc on osteoclast formation and bone resorption remain unknown. Thus, in this study, we examined the effects of αTP-suc on osteoclast differentiation and bone resorbing activity in inflammatory bone loss model. Methods: Osteoclast differentiation assay was performed by cocultures of mouse bone marrow cells and calvarial osteoblasts in culture media including interleukin-1 (IL-1). Osteoclasts were stained for tartrate-resistant acid phosphatase (TRAP). The level of receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). ICR mice were administered an intraperitoneal injections of αTP-suc or dimethyl sulfoxide (DMSO) 1 day before the implantation of a freeze-dried collagen sponge loaded with phosphate-buffered saline (PBS) or IL-1 over the calvariae and every other day for 7 days. The whole calvariae were obtained and analyzed by micro-computed tomography (CT) scanning, and stained for TRAP. Results: αTP-suc inhibits osteoclast formation in cocultures stimulated by IL-1 and decreased the level of expression of RANKL mRNA in osteoblasts. In addition, administered intraperitoneal injections of αTP-suc prevented IL-1-mediated osteoclast formation and bone loss in vivo. Conclusion: Our findings suggest that αTP-suc may have therapeutic value for treating and preventing bone-resorptive diseases, such as osteoporosis.
Abstract
Objective: Osteoclasts are bone-resorbing multinucleated cells derived from the monocyte/macrophage lineage during normal and pathological bone turnover. Recently, several studies revealed that alpha-tocopheryl succinate (αTP-suc)have demonstrated potent anti-cancer activities in vitro and in vivo. However, the effects of αTP-suc on osteoclast formation and bone resorption remain unknown. Thus, in this study, we examined the effects of αTP-suc on osteoclast differentiation and bone resorbing activity in inflammatory bone loss model. Methods: Osteoclast differentiation assay was performed by cocultures of mouse bone marrow cells and calvarial osteoblasts in culture media including interleukin-1 (IL-1). Osteoclasts were stained for tartrate-resistant acid phosphatase (TRAP). The level of receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). ICR mice were administered an intraperitoneal injections of αTP-suc or dimethyl sulfoxide (DMSO) 1 day before the implantation of a freeze-dried collagen sponge loaded with phosphate-buffered saline (PBS) or IL-1 over the calvariae and every other day for 7 days. The whole calvariae were obtained and analyzed by micro-computed tomography (CT) scanning, and stained for TRAP. Results: αTP-suc inhibits osteoclast formation in cocultures stimulated by IL-1 and decreased the level of expression of RANKL mRNA in osteoblasts. In addition, administered intraperitoneal injections of αTP-suc prevented IL-1-mediated osteoclast formation and bone loss in vivo. Conclusion: Our findings suggest that αTP-suc may have therapeutic value for treating and preventing bone-resorptive diseases, such as osteoporosis.
참고문헌 (31)
- Karsenty G, "Reaching a genetic and molecular understanding of skeletal development", Dev Cell, 2, pp.389~406 (2002)
- Rodan GA, "Therapeutic approaches to bone diseases", Science, 289, pp.1508~1514 (2000)
- Tanaka S, "Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system", Immunol Rev, 208, pp.30~49 (2005)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Kong YY, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis", Nature, 397, pp.315~323 (1999)
- Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, pp.165~176 (1998)
- Tanaka S, "Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors", J Clin Invest, 91, pp.257~263 (1993)
- Xiong J, "Matrix-embedded cells control osteoclast formation", Nat Med, 17, pp.1235~1241 (2011)
- Evans HM, "On the existence of a hitherto unrecognized dietary factor essential for reproduction", Science, 56, pp.650~651 (1922)
- Aggarwal BB, "Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases", Biochem Pharmacol, 80, pp.1613~1631 (2010)
- Jiang Q, "gammatocopherol and its major metabolite, in contrast to alphatocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells", Proc Natl Acad Sci U S A, 97, pp.11494~11499 (2000)
- Prasad KN, "Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture", Cancer Res, 42, pp.550~555 (1982)
- Prasad KN, "Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review", J Am Coll Nutr, 22, pp.108~117 (2003)
- 하현일, "alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 406(4), pp.546~551 (2011), ACADEMIC PRESS INC ELSEVIER SCIENCE
- 이장희, "Trolox Prevents Osteoclastogenesis by Suppressing RANKL Expression and Signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, 284, pp.13725~13734 (2009), AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
- Ha H, "alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis", J Immunol, 176, pp.111~117 (2006)
- Kim HN, "Histone Deacetylase Inhibitor MS-275 Stimulates Bone Formation in Part by Enhancing Dhx36-Mediated TNAP Transcription", JOURNAL OF BONE AND MINERAL RESEARCH, 26(9), pp.2161~2173 (2011), WILEY-BLACKWELL
- Norazlina M, "Tocotrienols are needed for normal bone calcification in growing female rats", Asia Pac J Clin Nutr, 11, pp.194~199 (2002)
- S. Ima-Nirwana, "Effects of Tocopherols and Tocotrienols on Body Composition and Bone Calcium Content in Adrenalectomized Rats Replaced with Dexamethasone", Journal of Medicinal Food, 7(1), pp.45~51 (2004), 한국식품영양과학회
- Hermizi H, "Beneficial effects of tocotrienol and tocopherol on bone histomorphometric parameters in sprague-dawley male rats after nicotine cessation", Calcif Tissue Int, 84, pp.65~74 (2009)
- Mehat MZ, "Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats", J Bone Miner Metab, 28, pp.503~509 (2010)
- Fujita K, "Vitamin E decreases bone mass by stimulating osteoclast fusion", Nat Med, 18, pp.589~594 (2012)
- Arend WP, "Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis", Arthritis Rheum, 38, pp.151~160 (1995)
- Lorenzo JA, "Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy", Endocrinology, 139, pp.3022~3025 (1998)
- Abramson SB, "Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage", Rheumatology (Oxford), 41, pp.972~980 (2002)
- Miyaura C, "An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation", J Exp Med, 197, pp.1303~1310 (2003)
- Khanna S, "Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection", J Neurochem, 112, pp.1249~1260 (2010)
- Jiang Q, "Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases", Proc Natl Acad Sci U S A, 105, pp.20464~20469 (2008)
- Kitazawa R, "Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter", Biochem Biophys Res Commun, 290, pp.650~655 (2002)
- Kitazawa S, "Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter", J Cell Biochem, 89, pp.771~777 (2003)
- Staal A, "Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor", retinoid X receptor complexes with vitamin E response elements, 1996, pp.137, 2001~2011